St Jude Medical has launched Trifecta aortic stented tissue valve in Canada, for patients with diseased, damaged or malfunctioning aortic heart valves and the tissue valve.
St Jude Medical claims the Trifecta valve is a clinically proven replacement valve and has a tri-leaflet stented pericardial design, manufactured from pericardial tissue attached to the exterior of the valve stent and offers hemodynamic performance.
The design allows the leaflets to open more fully and efficiently, mimicking the performance of a healthy aortic heart valve, while also mitigating tissue abrasion through tissue-to-tissue (stent-to-leaflet) contact.
The Trifecta valve is constructed using a polyester and tissue-covered titanium stent, or base, to ensure structural integrity of the valve and is designed to be implanted in the supra-annular aortic position.
Additional attributes of the Trifecta valve include proprietary tissue fixation and the St Jude Medical patented Linx AC Technology, an anti-calcification treatment designed to reduce tissue mineralization (hardening).
St Jude Medical Cardiovascular Division president Frank Callaghan said the company has developed an aortic stented tissue valve that is specifically designed for improved hemodynamic performance, durability and implantability.
"The Trifecta valve has demonstrated outstanding hemodynamic performance, improving the quality of life for patients with diseased aortic heart valves. We look forward to continuing to grow our legacy of market-leading valves with this advanced technology and will continue to put more control in the hands of physicians who treat cardiac patients worldwide," Callaghan said.
The Trifecta valve offers several features that improve the ease of implantation, including the valve’s holder, designed to improve visibility and cuff access for suturing, and the valve’s simplified sizing process, offering physicians more control in choosing the appropriate replacement valve for each patient’s heart.